Therapeutic Antibodies – News and Features

Researchers have identified a mechanism by which triple-negative breast cancer (TNBC) cells resist immunotherapy. By studying the role of ceramide synthase 4, they restored sensitivity to immunotherapy in a preclinical model.

The monoclonal antibody SC27 effectively neutralizes numerous SARS-CoV-2 variants and related coronaviruses. SC27 targets multiple sites on the spike protein, showing broad protection in lab tests and animal models.

A light-controlled "appetizer" that stimulates macrophages can increase their appetite for cancer cells, finds a new study.

A drug effective in treating breast cancer shows new promise in addressing breast cancer with brain metastases.

In this interview, Technology Networks spoke with Dr. Roy Maute, co-founder and CEO of Pheast Therapeutics, to learn about macrophage checkpoint therapies and the potential they hold for cancer treatment.

In this interview, Technology Networks spoke to Dr. Martin Vollmer, biopharma program manager within the Life Science Analysis Group at Agilent, to learn about the current analytical challenges the biopharma industry faces and how they are being addressed.

The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on the surface of T cells.

Sneaking by cancer’s defenses, by disguising tumor-fighting antibodies inside the molecules cancer uses to nourish tumor growth, is the basis of a novel therapy from Yale Cancer Center researchers at the Yale School of Medicine (YSM).

Early findings from a small clinical trial provide evidence that a new cellular immunotherapy approach may effectively treat metastatic solid tumors.

In this article, one of the leading quality control strategies being implemented by pharmaceutical manufacturers is discussed.